
Q3 2022 Investor Audibles: Third Point Capital, Ensemble Capital, Greenlight Capital
Value Hive Podcast
00:00
Third-Path Investing in Ventix
Ventix is a biotechnology company focused on treating autoimmune diseases by discovering and developing next-generation small molecule drugs for well-validated targets. Third-point first invested in Ventix in 2016 as an investment in Opelian, which was developing in an oral small molecule for ulcerative colitis with a post-money valuation of roughly $20 million. In early 2021, third-point along with management agreed to merge our opelian investment into Ventix to consolidate all autoimmune disorder assets run by the same management team under one company. We found the consolidated R&D pipeline, especially Ventix's TYK2 inhibitor commercially very attractive. The merger allowed the company to bulk
Transcript
Play full episode